Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Apellis Pharmaceuticals (APLS) Return on Capital Employed (2020 - 2025)

Apellis Pharmaceuticals (APLS) has 6 years of Return on Capital Employed data on record, last reported at 0.07% in Q4 2025.

  • For Q4 2025, Return on Capital Employed rose 13.0% year-over-year to 0.07%; the TTM value through Dec 2025 reached 0.07%, up 13.0%, while the annual FY2025 figure was 0.08%, 15.0% up from the prior year.
  • Return on Capital Employed reached 0.07% in Q4 2025 per APLS's latest filing, down from 0.31% in the prior quarter.
  • Across five years, Return on Capital Employed topped out at 0.31% in Q3 2025 and bottomed at 0.93% in Q4 2023.
  • Average Return on Capital Employed over 5 years is 0.39%, with a median of 0.31% recorded in 2024.
  • Peak YoY movement for Return on Capital Employed: tumbled -71bps in 2023, then surged 87bps in 2024.
  • A 5-year view of Return on Capital Employed shows it stood at 0.27% in 2021, then tumbled by -234bps to 0.92% in 2022, then fell by -2bps to 0.93% in 2023, then surged by 94bps to 0.06% in 2024, then skyrocketed by 228bps to 0.07% in 2025.
  • Per Business Quant database, its latest 3 readings for Return on Capital Employed were 0.07% in Q4 2025, 0.31% in Q3 2025, and 0.11% in Q2 2025.